Results 151 to 160 of about 5,702,542 (372)
Nature Communications, 2018 Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and resistance to anticancer therapies highlighting the potential of Mcl-1 ...
A. Tron +36 more
semanticscholar +1 more source
American Journal of Hematology, EarlyView.ABSTRACT In the Phase 3 DREAMM‐7 study of patients with relapsed/refractory multiple myeloma (RRMM) who received ≥ 1 prior therapy, belantamab mafodotin plus bortezomib and dexamethasone (BVd) demonstrated a progression‐free survival (PFS) benefit versus daratumumab plus bortezomib and dexamethasone (DVd).
Joshua Richter +13 more
wiley +1 more source
Multiple-Myeloma proteins.I. Immunological studies [PDF]
, 1956 Leonhard Korngold, Rose Lipari
openalex +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese patients with B‐cell malignancies.
Tingting Yao +5 more
wiley +1 more source
URETHANE (ETHYL CARBAMATE) THERAPY IN MULTIPLE MYELOMA [PDF]
, 1949 J. PHILIP LOGE, R. Wayne Rundles
openalex +1 more source
Is Enhancer Function Driven by Protein–Protein Interactions? From Bacteria to Leukemia
BioEssays, EarlyView.Enhancers are key regulatory elements that are conceptually conserved from bacteria to humans. Enhancer dysregulation is common in cancers, including leukemia. We argue that highly specific protein–protein interactions, including transcription factors, mediate enhancer‐promoter proximity to allow enhancer‐bound factors to directly act on RNA polymerase
Nicholas T. Crump, Thomas A. Milne
wiley +1 more source
Role of minimal residual disease assessment in multiple myeloma
HaematologicaMultiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with different outcomes. With the advent of very efficient therapies including
Raphael Szalat +2 more
doaj +1 more source
A Bayesian joint model of multiple longitudinal and categorical outcomes with application to multiple myeloma using permutation-based variable importance [PDF]
arXivJoint models have proven to be an effective approach for uncovering potentially hidden connections between various types of outcomes, mainly continuous, time-to-event, and binary. Typically, longitudinal continuous outcomes are characterized by linear mixed-effects models, survival outcomes are described by proportional hazards models, and the link ...
arxiv
Multiple Myeloma Treated with Stilbamidine and Pentamidine [PDF]
, 1948 A. E. Brewer
openalex +1 more source